Navigation Links
Bend Research Receives Patent for Technology That Enhances the Bioavailability of Low-Solubility Drugs

BEND, Ore., April 7, 2011 /PRNewswire/ -- Bend Research Inc. (, a leading independent drug-formulation development and manufacturing company, announced that it has received a new U.S. patent covering the use of polymer additives to improve and sustain the bioavailability of low-solubility drugs in the human body.

The patent protects formulations that enhance the absorption of low-solubility drugs by blending the drug with an additive, resulting in improved bioavailability.  There is a growing need for this technology, since it is estimated that more than 40% of drugs in development have low aqueous solubility.  Use of these polymer additives means lower drug doses can be used to achieve better therapies for these drugs.  The technology works by sustaining high concentrations of drug in the gastrointestinal tract.

"This technology is on target with our mission of advancing our clients' best new medicines," said Bend Research President and CEO Rod Ray.  "It provides one more way we can help our customers provide novel therapies to treat illnesses that desperately need new approaches."

"Pharmaceutical industry leaders acknowledge that discovering and bringing these new compounds forward is very complicated," Ray observed, "and Bend Research scientists and engineers are well known for providing key assistance to leading pharmaceutical companies facing this challenge."

The patent covers blending solubility-improved drug forms with solubility-enhancing polymer additives. Drug forms covered by the patent are nanoparticles, absorbed drugs, drugs in nanosuspensions, supercooled drug melts, cyclodextrin/drug forms, gelatin dosage forms, and soft-gel dosage forms. Often, such drug forms dissolve rapidly in the GI tract and then precipitate to low-solubility forms before they can be absorbed.  Blending these drug forms with a solubility-enhancing polymer provides a simple way to keep the compounds in solution so they can be absorbed.  Solubility-enhancing polymers sustain high concentrations of drug in the GI tract by inhibiting crystallization or precipitation of the drug to a lower-solubility drug form.

The patent is one in a growing number of formulation- and process-related patents associated with Bend Research's solubility-enhancing drug-formulation technologies.  These solubilization technologies enhance the concentration of drug in patients' bloodstreams and enable faster drug dissolution than is possible with crystalline drug forms.

The patent, which is titled "Pharmaceutical Compositions Comprising Drug and Concentration-Enhancing Polymers," was assigned Patent No. 7,887,840 by the U.S. Patent and Trademark Office.  The inventors are Dwayne Friesen, Bend Research Vice President of Research, and former Pfizer employee William Curatolo.  The patent is assigned to Bend Research Inc.

This patent complements a number of patents that use spray-drying to create amorphous dispersions. The technology covered by this patent does not require spray-drying or hot-melt extrusion (HME) formulation to improve bioavailability, but rather involves conventional blending of the drug form with a polymer additive.  Bend Research technologies have successfully enabled the advancement of hundreds of compounds from preclinical studies to several large Phase 3 clinical trials.

About Bend Research Inc.

For more than 30 years, Bend Research has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems. This success is based on the company's ability to develop, advance, and commercialize pharmaceutical technologies.  The firm's innovative drug-delivery solutions grow from a solid base of scientific and engineering fundamental understanding.

Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical-trial quantities of drug candidates in its cGMP facility, and advances promising drug candidates from conception through commercialization.  Bend Research is a leader in novel formulations, including solubilization technologies such as spray-dried dispersions and hot-melt extrusion formulations, as well as controlled-release, inhalation, and biotherapeutics technologies.

Bend Research has more than 200 employees based in four state-of-the-art facilities in Bend, Oregon, USA.

For more information about Bend Research and its formulation and manufacturing capabilities, please contact Dana Settell via email at or phone at 541-382-4100.

SOURCE Bend Research Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MITs Koch Institute to use Roche LightCycler 480 System to Help Advance Cancer Research
2. Dendreon Announces Presentation of Data at the American Association of Cancer Research Annual Meeting
3. Oxford BioTherapeutics Licenses BioWas POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
4. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
5. Berg Diagnostics Launches Molecular Diagnostics Services and Products at American Association for Cancer Research (AACR) 102nd Annual Meeting
6. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
7. S&P Equity Research Picks COV Focus Stock of the Week
8. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
9. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
10. GSK Publishes Payments for Research, Consulting and Advising by U.S. Healthcare Professionals
11. Syndax Pharmaceuticals Announces Entinostat Data at 102nd Annual American Association for Cancer Research Meeting
Post Your Comments:
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
(Date:11/25/2015)... , Nov. 25, 2015 On ... first federal bellwether trial against Wright Medical Technology, ... to their Conserve metal-on-metal hip implant device, awarded ... Following a two week trial and three days ... metal-on-metal hip device was defectively designed and unreasonably ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... through sharing, the 2016 Building Better Radiology Marketing Programs meeting will ... on Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping ... platform for mental health and wellness consultation, has collaborated with a leading web-based ... the knowledge gap experienced by parents and bring advice from parenting experts within ...
(Date:11/27/2015)... ... 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his ... is one of Joplin's most famous and beautiful concert posters. The concert was held ... Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's stardom ...
(Date:11/26/2015)... Cambridge, ON (PRWEB) , ... November 26, 2015 ... ... availability of a real-time eReferral system for diagnostic imaging in the Waterloo region. ... mammography, BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) ...
(Date:11/26/2015)... ... 26, 2015 , ... PRMA Plastic Surgery is updating their record books yet ... 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, ... lives and it’s an honor to have served all of these women.” , PRMA ...
Breaking Medicine News(10 mins):